231 related articles for article (PubMed ID: 17608466)
1. Synthesis and biological evaluation of N-pyrazolyl-N'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis.
Bruno O; Brullo C; Bondavalli F; Schenone S; Ranise A; Arduino N; Bertolotto MB; Montecucco F; Ottonello L; Dallegri F; Tognolini M; Ballabeni V; Bertoni S; Barocelli E
J Med Chem; 2007 Jul; 50(15):3618-26. PubMed ID: 17608466
[TBL] [Abstract][Full Text] [Related]
2. 1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors.
Bruno O; Brullo C; Bondavalli F; Schenone S; Spisani S; Falzarano MS; Varani K; Barocelli E; Ballabeni V; Giorgio C; Tognolini M
Bioorg Med Chem; 2009 May; 17(9):3379-87. PubMed ID: 19362486
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
4. N-Aryl-2-phenyl-2,3-dihydro-imidazo[1,2-b]pyrazole-1-carboxamides 7-substituted strongly inhibiting both fMLP-OMe- and IL-8-induced human neutrophil chemotaxis.
Brullo C; Spisani S; Selvatici R; Bruno O
Eur J Med Chem; 2012 Jan; 47(1):573-9. PubMed ID: 22152986
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
6. 2-Phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives: new potent inhibitors of fMLP-induced neutrophil chemotaxis.
Bruno O; Brullo C; Bondavalli F; Ranise A; Schenone S; Falzarano MS; Varani K; Spisani S
Bioorg Med Chem Lett; 2007 Jul; 17(13):3696-701. PubMed ID: 17475488
[TBL] [Abstract][Full Text] [Related]
7. 6-amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis.
Cesarini S; Spallarossa A; Ranise A; Bruno O; Arduino N; Bertolotto M; Dallegri F; Tognolini M; Gobbetti T; Barocelli E
Bioorg Med Chem; 2009 May; 17(10):3580-7. PubMed ID: 19394230
[TBL] [Abstract][Full Text] [Related]
8. Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis.
Quan JM; Martin TR; Rosenberg GB; Foster DC; Whitmore T; Goodman RB
Biochem Biophys Res Commun; 1996 Feb; 219(2):405-11. PubMed ID: 8605000
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of signaling pathways by two new imidazo-pyrazoles molecules in fMLF-OMe- and IL8-stimulated human neutrophil.
Selvatici R; Brullo C; Bruno O; Spisani S
Eur J Pharmacol; 2013 Oct; 718(1-3):428-34. PubMed ID: 23978569
[TBL] [Abstract][Full Text] [Related]
10. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
[TBL] [Abstract][Full Text] [Related]
11. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors.
Hammond ME; Lapointe GR; Feucht PH; Hilt S; Gallegos CA; Gordon CA; Giedlin MA; Mullenbach G; Tekamp-Olson P
J Immunol; 1995 Aug; 155(3):1428-33. PubMed ID: 7636208
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents.
Bekhit AA; Ashour HM; Abdel Ghany YS; Bekhit Ael-D; Baraka A
Eur J Med Chem; 2008 Mar; 43(3):456-63. PubMed ID: 17532544
[TBL] [Abstract][Full Text] [Related]
13. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
[TBL] [Abstract][Full Text] [Related]
14. Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2.
Li F; Gordon JR
Biochem Biophys Res Commun; 2001 Aug; 286(3):595-600. PubMed ID: 11511101
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
[TBL] [Abstract][Full Text] [Related]
16. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
17. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms involved in the inhibition of neutrophil locomotion by tumor cells.
Amar M; Pham Huu T; Amit N; Hakim J
Blood Cells; 1993; 19(1):177-84; discussion 185-7. PubMed ID: 8400309
[TBL] [Abstract][Full Text] [Related]
20. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells.
Suzuki K; Adachi R; Hirayama A; Watanabe H; Otani S; Watanabe Y; Kasahara T
Br J Haematol; 2005 Sep; 130(5):681-90. PubMed ID: 16115123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
